Exhibit 99.2
˥
August 18 , 2026 EARNINGS CALL Q 2 2026
FORWARD LOOKING STATEMENT This presentation contains "forward - looking statements" relating to future events, and Evogene Ltd. ( the “ Company ” ) , may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered “ forward - looking statements ” as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the “ PSLRA ” ) and other securities laws , as amended. Statements that are not statements of historical fact may be deemed to be forward - looking statements . Such forward - looking statements may be identified by the use of such words as “ believe ” , “ expect ” , “ anticipate ” , “ should ” , “ planned ” , “ estimated ” , “ intend ” and “ potential ” or words of similar meaning. We are using forward - looking statements in this presentation when we discuss our value drivers, commercialization efforts and timing , product development and launches, estimated market size s and milestones , pipeline, as well as our capabilities and technology. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward - looking statements that may be made in this presentation. Therefore, actual future results, performance or achievements, and trends in the future may differ materially from what is expressed or implied by such forward - looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, the aftermath of the recent war between Israel and each of ( i ) the terrorist groups, Hamas and Hezbollah, (ii) Iran, and (iii) other regional terrorist groups supported by Iran, and any destabilizations in Israel, neighboring territories or the Middle East region, and those described in greater detail in Evogene's Annual Report on Form 20 - F and in other information Evogene files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading “ Risk Factors ” . Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions. The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or the Company , nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract , commitment or relating thereto or to the securities of Evogene or the Company . The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services . 2
EARNINGS CALL Q 2 2026 AGENDA • Opening Remarks - By Nir Nimrodi, Evogene ’ s Chairman • CEO Update – By Ofer Haviv • Financial Report Review – By Polina Ravzin • Q&A
EVOGENE PIONEERS REAL - WORLD INNOVATION Using a proprietary generative AI engine, we generate novel and highly potent small molecules, optimized across multiple - parameters, for the pharmaceutical and ag - chemical industries 4
• Established ChemPass AI as our core platform – developing a first - in - class generative AI foundation model for small molecules and integrating autonomous AI Agents in partnership with Google Cloud. • Validated the commercial value of our technology - secured 6 drug development agreements with leading biotechnology companies and premier academic institutions. • Built a lean and agile organization - reduced headcount from 117 to 38 employees, enabling greater focus and operational efficiency. • Significantly reduced cash burn - from approximately $ 20.5 M in 2024 to an expected $ 8.5 – 9.5 M in 2026 , with further reductions anticipated in 2027 . • Strengthened our financial runway - raised approximately $ 11.1 M in new capital to support execution of our strategic priorities. • Focused and monetized our portfolio - monetized Lavie Bio (sold to ICL for ~$ 15.25 M), licensed Biomica ’ s Phase I asset to Lishan Biotech, focused Casterra on Brazil's SAF market. EVOGENE TRANSFORMATION IN THE LAST 18 MONTHS BUILDING A LEAN, AI - DRIVEN COMPANY
GEN AI ENGINE Growing number of collaborations for a diverse pipeline of drug candidates Proven strategic collaborations driving our ag - chem pipeline PIONEERING IN PHARMA REVOLUTIONIZING AG OUR STORY ChemPass AI - computational engine for the generation & optimization of small molecules
EARNINGS CALL Q 2 2026 AGENDA • Opening Remarks - By Nir Nimrodi, Evogene ’ s Chairman • CEO Update – By Ofer Haviv • Financial Report Review – By Polina Ravzin • Q&A
8 PHARMA DIVISION – DRUGS Demyelination Disorders Neutrophil - Derived Inflammatory Diseases Metabolic Disease Therapy Resistant Lung Cancer Herbicides INTERNAL PIPELINE Wheat Blotch AG DIVISION* – AG - CHEMICALS AG DIVISION ͐ – Operations in this field are conducted through our subsidiary, AgPlenus . Cardiovascular Diseases HARNESSING THE POWER OF CHEMPASS AI FOR REAL - WORLD INNOVATION On cology Disease Undisclosed
DIVERSIFIED DRUG DISCOVERY PIPELINE – (INITIATED Q 4 / 25 ) PARTNER IND PRE - CLINICAL LEAD OPTIMIZATION HIT - TO - LEAD HIT ID PREPROCESSING PROGRAM INDICATION COLLABORATIONS Undisclosed EVG - O 311 Oncology EVG - M 410 Metabolism* EVG - I 110 Immunology EVG - N 210 Neurology EVG - O 310 Oncology EVG - C 610 Cardiology INTERNAL PIPELINE EVG - R 510 Undisclosed * Non - protein target PHARMA DIVISION
END - TO - END PROCESS – NOVEL, HIGHLY POTENT, OPTIMIZED MOLECULE HIT SCREENING WITH POINTHIT TM LEAD OPTIMIZATION WITH LEADOP GPT TM Step 1 Step 3 HIT TO LEAD WITH ACTIVESEARCH TM 5 ( 3 %) 164 Step 2 38 ( 23 %) In Vivo Activity 2 ( 0.5 %) 11 ( 2.5 %) Enzymatic Activity 440 Ordered Compounds Ordered Compounds 33 ( 54 %) 61 56 ( 92 %) PROPRIETARY PRODUCT CANDIDATE TARGET PROTEIN New MOA - no available crystallographic structure with limited computational data Enzymatic Activity In Vivo Activity Ordered Compounds Enzymatic Activity In Vivo Activity 10 * Performed by AgPlenus, Evogene ’ s wholly owned subsidiary EVOGENE'S SUBSIDIARY *
BOAZ MAOZ, MANAGING DIRECTOR, GOOGLE CLOUD ISRAEL AGENTS' INTEGRATION “ This expanded collaboration with Evogene demonstrates the power of integrating cutting - edge artificial intelligence into scientific research . By leveraging our technology to deploy advanced AI agents, we are enabling Evogene to automate and scale their complex discovery workflows . This foundation accelerates the speed and precision of identifying small molecules, further cementing Evogene's role as a leader in next - generation molecular design for the pharmaceutical and agricultural industries ” addressi ng product challeng es from day 0 11 TECHNOLOGICAL ACHIVMENT DURING THR FIRST HALF OF 2026 EXPANDED CHEMPASS AI TM VIRTUAL LIBRARY BY 300 % TO 110 BILLION UNIQUE, ENUMERATED, VENDOR - ACCESSIBLE COMPOUNDS E nabling AI - driven exploration of broader chemical space for novel pharmaceutical and agrochemical candidates. NOVEL AI MODEL FOR PREDICTING ANTIFUNGAL POTENCY Enables ChemPass AI for Ag to identify and prioritize antifungal molecules with a higher probability of biological success at early discovery stages.
12 PHARMA DIVISION – DRUGS EVOGENE – LOOKING FORWARD AG DIVISION* – AG - CHEMICALS AG DIVISION* – Operations in this field are conducted through our subsidiary, AgPlenus . ADDITIONAL TECH COLLABORATIONS TO MAINTAIN OUR COMPETITIVE ADVANTAGE • Progress in existing pipeline • New collaborations with biotech companies and academic institutions • Building relationships with pharmaceutical companies • Evaluation of projects for an internal pipeline • Progress in existing pipeline • New collaborations with ag - chem companies • Evaluation of projects for expanding internal pipeline
EARNINGS CALL Q 2 2026 AGENDA • Opening Remarks - By Nir Nimrodi, Evogene ’ s Chairman • CEO Update – By Ofer Haviv • Financial Report Review – By Polina Ravzin • Q&A
˥˨ 14 EVOGENE SUBSIDIARIES ’ ACTIVITY
CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION U.S. dollars in thousands | Unaudited June 30 , 2026 Dec. 31 , 2025 June 30 , 2026 Dec. 31 , 2025 ASSETS LIABILITIES AND EQUITY Current assets Cash and cash equivalents 9,316 12,956 Restricted cash 35 32 Trade receivables 384 317 Other receivables and prepaid expenses 1,026 1,565 Deferred expenses related to issuance of warrants – 551 Inventories 93 210 Total current assets 10,854 15,631 Long - term assets Long - term deposits and other receivables 531 571 Investment accounted for using the equity method – 43 Deferred expenses related to issuance of warrants – 1,165 Right - of - use assets 1,558 1,824 Property, plant and equipment, net 497 812 Total long - term assets 2,586 4,415 TOTAL ASSETS 13,440 20,046 Current liabilities Trade payables 394 639 Employees and payroll accruals 911 861 Lease liabilities 668 716 Liabilities in respect of government grants 89 56 Deferred revenues and other advances 21 17 Warrants and pre - funded warrants liability 659 706 Other payables 302 449 Total current liabilities 3,044 3,444 Long - term liabilities Lease liabilities 1,433 1,482 Liabilities in respect of government grants 3,130 3,073 Deferred revenues and other advances 65 72 Total long - term liabilities 4,628 4,627 TOTAL LIABILITIES 7,672 8,071 Shareholders' equity Ordinary shares 804 488 Share premium and other capital reserves 286,100 281,986 Accumulated deficit ( 290,194 ) ( 282,556 ) Equity attributable to equity holders of the Company ( 3,290 ) ( 82 ) Non - controlling interests 9,058 12,057 TOTAL EQUITY 5,768 11,975 TOTAL LIABILITIES AND EQUITY 13,440 20,046 Q 2 2026
CONSOLIDATED INTERIM STATEMENTS OF PROFIT OR LOSS U.S. dollars in thousands (except share and per share amounts) | Unaudited Six months ended June 30 , Three months ended June 30 , Year ended Dec. 31 , 2026 2025 (*) 2026 2025 (*) 2025 (*) Audited Unaudited Revenues 681 2,877 347 534 3,503 Cost of revenues: Inventory impairment – – – – 2,180 Other cost of revenues 336 1,653 206 136 1,914 Total Cost of Revenues 336 1,653 206 136 4,094 Gross profit 345 1,224 141 398 ( 591 ) Operating expenses: Research and development, net 2,938 3,502 1,374 1,673 6,262 Sales and marketing 708 703 319 354 1,359 General and administrative 1,984 2,063 889 983 4,021 Other expenses (income) 102 ( 191 ) 122 – ( 205 ) Total operating expenses, net 5,732 6,077 2,704 3,010 11,437 Operating loss ( 5,387 ) ( 4,853 ) ( 2,563 ) ( 2,612 ) ( 12,028 ) Financing income 2,304 1,839 1,140 236 2,618 Financing expenses ( 4,045 ) ( 1,011 ) ( 168 ) ( 569 ) ( 1,841 ) Financing income (expenses), net ( 1,741 ) 828 972 ( 333 ) 777 Share of loss from equity accounted investment ( 43 ) ( 66 ) – ( 64 ) ( 39 ) Loss before taxes on income ( 7,171 ) ( 4,091 ) ( 1,591 ) ( 3,009 ) ( 11,290 ) Taxes on income (tax benefit) – 1 – 1 1 Loss from continuing operations ( 7,171 ) ( 4,092 ) ( 1,591 ) ( 3,010 ) ( 11,291 ) Income (loss) from discontinued operations, net ( 492 ) ( 3,579 ) ( 176 ) ( 1,671 ) 3,464 LOSS $ ( 7,663 ) ( 7,671 ) $ ( 1,767 ) ( 4,681 ) $ ( 7,827 ) (*) Reclassified to conform to the current period presentation, following the classification of certain operations as discont inu ed operations. Q 2 2026
EARNINGS CALL Q 2 2026 AGENDA • Opening Remarks - By Nir Nimrodi, Evogene ’ s Chairman • CEO Update – By Ofer Haviv • Financial Report Review – By Polina Ravzin • Q&A
THANK YOU